How Much Do You Know?

Which cells are involved in vaso-occlusion and VOCs?

All blood cells
Red blood cells
Endothelial cells

Correct : In the chronic inflammatory environment of SCD, clusters of all blood cells drive ongoing, silent vaso-occlusion that can culminate in VOCs.1-3

Incorrect : In the chronic inflammatory environment of SCD, clusters of all blood cells drive ongoing, silent vaso-occlusion that can culminate in VOCs.1-3

Incorrect : In the chronic inflammatory environment of SCD, clusters of all blood cells drive ongoing, silent vaso-occlusion that can culminate in VOCs.1-3

1. Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin. 2009;33(1):1-16. 2. Puri L, Nottage KA, Hankins JS, Anghelescu DL. State of the art management of acute vaso-occlusive pain in sickle cell disease. Paediatr Drugs. 2018;20(1):29-42. 3. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801-809. 4. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647-3656. 5. Brandow AM, Zappia KJ, Stucky CL. Sickle cell disease: a natural model of acute and chronic pain. Pain. 2017;158(Suppl 1):S79-S84. doi.10.1097/j.pain.0000000000000824. 6. Ansari J, Gavins F. Ischemia-reperfusion injury in sickle cell disease: from basics to therapeutics. Am J Pathol. 2019;189(4):706-718. 7. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease. Expert Panel Report, 2014. https://www.nhlbi.nih.gov/health-topics/ evidence-based-management-sickle-cell-disease. 8. Novelli E, Gladwin M. Crises in sickle cell disease. Chest. 2016;149(4):1082-1093. 9. Brousse V, Buffet, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Hematol. 2014 Jul;166(2):165- 176. 10. Shah R, Taborda C, Chawla S. Acute and chronic hepatobiliary manifestations of sickle cell disease: a review. World J Gastrointest Pathophysiol. 2017;8(3):108-116. 11. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015; 11(3):161-171. doi: 10.1038/nrneph.2015.8. 12. Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89(5):530-535. 13. Shah N, Bhor M, Xie L, et al. Sickle cell disease complications: prevalence and resource utilization. PLoS ONE. 2019;14(70);1-12. 14. Smith WR, Pemberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101. 15. Kanter J, Gibson R, Lawrence RH, et al. Perceptions of US adolescents and adults with sickle cell disease on their quality of care. JAMA Network Open. 2020 May 1;3(5):e206016. doi.10.1001/jamanetworkopen.2020.6016. 16. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17-25.

 

 

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.

1/21 SDC-1236447